Target type: biologicalprocess
Any process that activates, maintains or increases the frequency, rate or extent of cholinergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter acetylcholine. [GOC:mah]
Positive regulation of synaptic transmission, cholinergic refers to the process by which the strength or efficiency of cholinergic synapses is increased. Cholinergic synapses are those that utilize acetylcholine as their primary neurotransmitter. This process is essential for normal nervous system function and is involved in a wide range of physiological processes, including learning, memory, and muscle contraction.
Here's a more detailed breakdown of the biological process involved:
1. **Presynaptic Events:**
* **Increased acetylcholine synthesis:** Enzymes involved in acetylcholine synthesis, such as choline acetyltransferase, are upregulated. This leads to a greater production of acetylcholine within the presynaptic neuron.
* **Increased acetylcholine release:** The release of acetylcholine from synaptic vesicles into the synaptic cleft is enhanced. This can occur through several mechanisms, including:
* **Increased vesicle docking and fusion:** The number of synaptic vesicles ready for release at the presynaptic terminal is increased.
* **Increased calcium influx:** Calcium ions (Ca2+) play a crucial role in triggering neurotransmitter release. Factors that enhance calcium influx into the presynaptic terminal, such as increased calcium channel activity, will promote acetylcholine release.
* **Reduced acetylcholine reuptake:** The reuptake of acetylcholine from the synaptic cleft back into the presynaptic neuron is inhibited. This allows acetylcholine to remain in the synapse longer, prolonging its effects on the postsynaptic neuron.
2. **Postsynaptic Events:**
* **Increased acetylcholine receptor expression:** The number of acetylcholine receptors (nAChRs and mAChRs) on the postsynaptic membrane is increased. This enhances the postsynaptic neuron's sensitivity to acetylcholine.
* **Increased receptor sensitivity:** The responsiveness of acetylcholine receptors to acetylcholine is enhanced, leading to a stronger postsynaptic response. This can involve changes in receptor phosphorylation or other modifications.
* **Signaling pathway activation:** Activation of downstream signaling pathways initiated by acetylcholine binding to its receptors is enhanced. This can include changes in gene expression, protein synthesis, and other cellular processes that ultimately contribute to the overall increase in synaptic strength.
3. **Modulatory Factors:**
* **Neuromodulators:** Various neurotransmitters and neuromodulators, such as dopamine, norepinephrine, and serotonin, can influence the activity of cholinergic synapses. Some of these modulators can enhance acetylcholine release or postsynaptic receptor function, contributing to positive regulation of synaptic transmission.
* **Synaptic plasticity:** The process of synaptic plasticity, where the strength of synapses can be modified over time, is crucial for positive regulation of cholinergic transmission. Long-term potentiation (LTP), a form of synaptic plasticity associated with learning and memory, is often observed at cholinergic synapses and contributes to their enhanced function.
Positive regulation of cholinergic synaptic transmission is a complex process involving multiple cellular and molecular mechanisms. It is a critical process for normal brain function and is disrupted in various neurological disorders. Understanding these mechanisms is essential for developing therapeutic strategies to treat conditions associated with impaired cholinergic transmission.'
"
Protein | Definition | Taxonomy |
---|---|---|
Substance-P receptor | A substance-P receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25103] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
astemizole | astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects. | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
econazole | 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. Econazole: An imidazole derivative that is commonly used as a topical antifungal agent. | dichlorobenzene; ether; imidazoles; monochlorobenzenes | |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
paroxetine | paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression. | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor |
phenylalanylphenylalanylamide | |||
cp 96345 | CP 96345: structure given in first source; potent nonpeptide antagonist of the substance P (NK1) receptor; CP 96344 is enantiomer of CP 96345 | ||
sr 48968 | SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968 | ||
7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one | 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one: structure given in first source; RP 68651 is the inactive (3aS,7aS)-isomer; substance P antagonist | ||
senktide | |||
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine | (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine: structure given in first source | ||
l 703606 | L 703606: structure given in first source | ||
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist | ||
l 733060 | 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source | piperidines | |
win 64821 | WIN 64821: a dimerized Trp-Phe condensate; structurally similar to verticillins and chaetocins; a nonpeptide neurokinin antagonist; structure given in first source; substance P antagonist | ||
substance p, pro(9)- | substance P, Pro(9)-: RN given refers to the (L-Pro)-isomer; RN for cpd without isomeric designation not available 3/91 | ||
substance p, sar(9)-met(o2)(11)- | substance P, Sar(9)-Met(O2)(11)-: a neurokinin-1 receptor agonist | ||
ranatachykinin a | ranatachykinin A: a tachykinin in frog (Rana catesbeiana) brain and intestine | ||
sr 142806 | |||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
cp 99994 | 3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer | ||
neurokinin a | Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI. | ||
neurokinin b | Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS. | polypeptide | |
sb 223412 | SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source | ||
seglitide | seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist | ||
biphalin | biphalin: enkephalin dimer; two fragments of Ala(2)-enkephalin are connected by a diamine bridge to form above cpd; structure given in first source | ||
netupitant | netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. netupitant: orally active neurokinin-1 receptor antagonist | aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes | antiemetic; neurokinin-1 receptor antagonist |
sb 222200 | quinolines | ||
sb 218795 | SB 218795: structure in first source | quinolines | |
substance p (6-11), tyr(6)-d-phe(7)-d-his(9)- | substance P (6-11), Tyr(6)-D-Phe(7)-D-His(9)-: substance P antagonist | ||
vofopitant | |||
pd 154075 | PD 154075: a non-peptide tachykinin NK1 receptor antagonist; structure given in first source | ||
edotecarin | |||
(2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine | (2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine: structure given in first source | ||
vestipitant | |||
ly 306740 | LY 306740: LY-307679 is the inactive enantiomer | ||
sdz nkt 343 | SDZ NKT 343: structure in first source | ||
orvepitant | |||
zd 6021 | ZD 6021: structure in first source | ||
tak 637 | TAK 637: structure in first source | ||
casopitant | piperidines | ||
nkp 608 | |||
dnk 333 | DNK 333: a dual neurokinin NK1/NK2 receptor antagonist; structure in first source | ||
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
rolapitant | azaspiro compound; ether; organofluorine compound; piperidines; pyrrolidin-2-ones | antiemetic; neurokinin-1 receptor antagonist | |
spiroquinazoline | spiroquinazoline: isolated from the fungus Aspergillus flavipes; structure given in first source; substance P antagonist | ||
ditryptophenaline | ditryptophenaline: structure in first source | ||
serlopitant | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
aprepitant | aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist |
l 742694 | L 742694: a neurokinin-1 receptor antagonist; structure given in first source |